Reliability of assessment of urgency and other symptoms indicating anal sphincter, large bowel or urinary dysfunction

References

• Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–9
   PubMed Web of Science ®Google Scholar
• Adolfsson J, Steineck G, Whitmore WF, Jr. Recent results of management of palpable clinically localized prostate cancer. Cancer 1993; 72: 310–22
   PubMed Web of Science ®Google Scholar
• Adolfsson J, Helgason AR, Dickman P, Steineck G. Urinary and bowel symptoms in men with and without prostate cancer: results from an observational study in the Stockholm area. Eur Urol 1998; 33: 11–6
   PubMed Web of Science ®Google Scholar
• Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001; 166: 947–52
   PubMed Web of Science ®Google Scholar
• Penson DF. Quality of life following prostate cancer treatments. Curr Urol Rep 2000; 1: 71–7
   PubMedGoogle Scholar
• Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582–92
   PubMed Web of Science ®Google Scholar
• Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790–6
   PubMed Web of Science ®Google Scholar
• Al-Abany M, Helgason AR, Cronqvist AK, Svensson C, Wersall P, Steineck G. Long-term symptoms after external beam radiation therapy for prostate cancer with three or four fields. Acta Oncol 2002; 41: 532–42
   PubMed Web of Science ®Google Scholar
• Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 74: 2520–32
   PubMed Web of Science ®Google Scholar
• Yeoh EE, Botten R, Russo A, McGowan R, Fraser R, Roos D, et al. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys 2000; 47: 915–24
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76
   PubMed Web of Science ®Google Scholar
• Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472–83
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ, Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–57
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer 1994; 73: 2791–802
   PubMed Web of Science ®Google Scholar
• Donovan JL, Abrams P, Peters TJ, Kay HE, Reynard J, Chapple C, et al. The ICS-‘BPH’ Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996; 77: 554–62
   PubMedGoogle Scholar
• Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup AJ, et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995; 76: 451–8
   PubMedGoogle Scholar
• Bharucha AE, Locke GR III, Seide BM, Zinsmeister AR. A new questionnaire for constipation and faecal incontinence. Aliment Pharmacol Ther 2004; 20: 355–64
   PubMed Web of Science ®Google Scholar
• Talley NJ, Phillips SF, Melton J III, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med 1989; 111: 671–4
   PubMed Web of Science ®Google Scholar
• Helgason AR. Prostate cancer treatment and quality of life—a three-level epidemiological approach [Doctoral thesis]. Karolinska Institutet University Press, Stockholm 1997
   Google Scholar
• Steineck G, Bergmark K, Henningsohn L, al Abany M, Dickman PW, Helgason AR. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol 2002; 41: 244–52
   PubMed Web of Science ®Google Scholar
• Helgason AR, Arver S, Adolfsson J, Dickman P, Granath F, Steineck G. Potency’: the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test–retest reliability. Br J Urol 1998; 81: 135–41
   PubMedGoogle Scholar
• Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 2002; 81: 443–50
   PubMed Web of Science ®Google Scholar
• Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Steineck G. Distress due to unwanted side-effects of prostate cancer treatment is related to impaired well-being (quality of life). Prostate Cancer Prostatic Dis 1998; 1: 128–33
   PubMed Web of Science ®Google Scholar
• Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G. Distressful symptoms after radical cystectomy with urinary diversion for urinary bladder cancer: a Swedish population-based study. Eur Urol 2001; 40: 151–62
   PubMed Web of Science ®Google Scholar
• Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 2002; 62: 215–25
   PubMed Web of Science ®Google Scholar
• Henningsohn L, Steven K, Kallestrup EB, Steineck G. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 2002; 168: 168–74
   PubMed Web of Science ®Google Scholar
• Dos Santos Silva I. Cancer epidemiology: principles and methods2nd ed. IARC, LyonFrance 1999
   Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159–74
   PubMed Web of Science ®Google Scholar
• Gregoire JP, Moisan J, Labrecque M, Cusan L, Diamond P. Validation of a French adaptation of the international prostatic symptom score. Prog Urol 1996; 6: 240–9
   PubMedGoogle Scholar
• Lujan GM, Paez BA, Martin OE, Llanes GL, Berenguer SA. The validity of the IPSS questionnaire in a sample of 262 patients with benign prostatic hyperplasia. Arch Esp Urol 1997; 50: 847–53 (In Spanish)
   PubMedGoogle Scholar
• El Din KE, Koch WF, de Wildt MJ, Kiemeney LA, Debruyne FM, De La Rosette JJ. Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol 1996; 155: 1959–64
   PubMed Web of Science ®Google Scholar
• Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334
   Web of Science ®Google Scholar
• Nunnally J, Bernstein I. Psychometric theory3rd ed. McGraw-Hill, New York 1994
   Google Scholar